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structed on an advanced, entirely new technologi-
cal platform, much of which comes from our 
new publishing partner, Atypon. Our new Web 
site is just one part of the revolution in informa-
tion technology and delivery. Electronic delivery 
modes continue to proliferate. Social networks, 
intranets, mobile applications, tablet computers 
and e-readers, and text messaging are changing 
the patterns of communication and delivery of 
information for physicians, scientists, students, 
and patients. Our aim is to continue to develop 
new options for electronic information delivery 
that will be of interest, use, and value to all.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
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The Initiation of Renal-Replacement Therapy — Just-in-Time Delivery
Norbert Lameire, M.D., Ph.D., and Wim Van Biesen, M.D., Ph.D.
Renal-replacement therapy for patients with end-
stage renal disease was introduced approximately 
50 years ago, yet the optimal timing for the ini-
tiation of dialysis is still debated. In recent years 
there has been a trend toward initiating dialysis 
at a relatively high estimated glomerular filtration 
rate (GFR),1,2 based on the assumption that start-
ing dialysis early may avert the many medical and 
social problems associated with advanced uremia. 
For example, in 1996, only 19% of patients in the 
United States began dialysis therapy when the 
estimated GFR was higher than 10 ml per minute 
per 1.73 m2 of body-surface area (early initiation), 
but by 2005, 45% initiated dialysis early.3 Care for 
patients with end-stage renal disease requires mas-
sive economic and human resources. If many peo-
ple start dialysis early, the need for an increase 
in staff and resources for dialysis is inevitable. 
Furthermore, premature initiation of renal-replace-
ment therapy has a major impact on the daily life 
of a patient, given the personal burden of dialy-
sis. Thus, defining the optimal timing for the ini-
tiation of dialysis is extremely important.
Retrospective studies, with all their inherent 
weaknesses, did not show a survival benefit with 
early initiation of dialysis. On the contrary, pa-
tients who started dialysis with a relatively low 
creatinine clearance (“late start”) tended to survive 
longer.4,5 At least two recent studies attributed 
this somewhat unexpected finding to the higher 
number of coexisting conditions among patients 
who start dialysis at a higher estimated GFR.6,7 
In addition, calculation of the estimated GFR is 
based on the serum creatinine concentration. The 
calculation of estimated GFR, whether it is based 
on the commonly used Modification of Diet in 
Renal Disease (MDRD) equation or the Cockcroft–
Gault equation — or some other estimating equa-
tion — may be quite inaccurate when kidney func-
tion is extremely reduced. Although a low serum 
creatinine concentration generally indicates a bet-
ter GFR, a low creatinine concentration may also 
be caused by decreased muscle mass due to mal-
nutrition or may be induced by overhydration. 
In addition, the discussion of timing for the ini-
tiation of dialysis is confounded by the distinction 
between the timing of referral to the nephrolo-
gist and the timing of initiation of dialysis. Obvi-
ously, only patients who are referred to a nephrol-
ogist in a timely manner have the opportunity to 
plan the timing for the initiation of dialysis, be-
cause planned initiation requires appropriate care 
before dialysis is needed.8
In this issue of the Journal, Cooper et al.9 re-
port results from the Initiating Dialysis Early and 
Late (IDEAL) study, a multicenter, randomized, 
controlled trial in which adult patients who have 
progressive end-stage renal disease and are already 
receiving care in nephrology units were assigned 
to planned initiation of hemodialysis or perito-
neal dialysis when the estimated GFR was either 
10 to 14 ml per minute per 1.73 m2 (early start) 
or 5 to 7 ml per minute per 1.73 m2 (late start). 
The patients in the two study groups were well 
matched with respect to baseline characteristics. 
After a median follow-up period of 3.59 years, pa-
tient survival and the frequency of adverse events 
were not significantly different between the two 
groups; however, there was a 6-month separation 
between the groups in the start time of dialysis.
The study design of the trial allowed the in-
vestigators to base the timing of the initiation of 
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dialysis not only on the estimated GFR but also 
on the presence or new appearance of symptoms 
of uremia. In our view the appropriate use of this 
dual criterion is critical for the optimal interpre-
tation of the results.
Do the results of the IDEAL trial imply that the 
initiation of dialysis can be delayed until an es-
timated GFR of 5 to 7 ml per minute per 1.73 m2 
is reached? Certainly not. In the late-start group, 
322 patients (76%) had to initiate dialysis when 
the estimated GFR was far above the 5 to 7 ml 
per minute per 1.73 m2 range, owing to the de-
velopment of symptoms of uremia, fluid overload, 
or various other reasons (as detailed in the Sup-
plementary Appendix, available with the full text 
of the article at NEJM.org). As a result, the mean 
estimated GFR at the start of dialysis in the late-
start group was 9.8 ml per minute per 1.73 m2 
— far above the target of 5 to 7 ml per minute 
per 1.73 m2. We view this high number of nec-
essary protocol violations as indicating that in 
actual practice, clinical symptoms and patient fol-
low-up are of greater importance in decision mak-
ing than the estimated GFR. In other words, the 
presence of symptoms of uremia led to the ini-
tiation of dialysis in the majority of the patients 
in the late-start group. One may question whether 
the significant difference in estimated GFR be-
tween the groups at the time of the initiation of 
dialysis (a mean difference of 2.2 ml per minute 
per 1.73 m2) is clinically relevant, in view of the 
inaccuracy of estimated GFR in this low range. 
However, the important conclusion of the study 
is that waiting to initiate dialysis until signs of 
uremia appear does not jeopardize the patient and 
that starting renal-replacement therapy on the ba-
sis of a predefined estimated GFR value does not 
improve the outcome. Because the IDEAL study 
considered both estimated GFR and symptoms, 
the results of the study are difficult to compare 
with those of previous registry studies1,4,5 in which 
the decision to start dialysis early or late was 
based on estimated GFR alone and not on the 
presence of symptoms of uremia. Given the re-
sults of the study, the term “preemptive” initiation 
of dialysis may be used in the case of asymptom-
atic patients, as compared with “on-indication” 
initiation in the case of patients with symptoms 
or complications of uremia.
The main conclusion of this important study 
— that for asymptomatic patients renal-replace-
ment therapy can be delayed by an average of 
6 months — should be placed in perspective. An 
important prerequisite for a “wait and see” poli-
cy is careful clinical follow-up of each patient in 
order to avoid some of the life-threatening com-
plications of uremia that may necessitate imme-
diate renal-replacement therapy. All the patients 
in the trial had been followed for some time by 
their respective nephrologists and were well pre-
pared to start dialysis. The study protocol explic-
itly advocated that the method of dialysis be se-
lected, and a functioning peritoneal or vascular 
access be prepared, in advance, a policy that per-
mits the immediate initiation of dialysis if the 
patient becomes symptomatic. Indeed, few pa-
tients in either group started dialysis with the use 
of a temporary access catheter. Conversely, the re-
sults of the study also imply that among asymp-
tomatic patients, delaying the start of dialysis until 
a permanent access has been created does not 
jeopardize the outcome. Given the results of the 
study, the use of temporary catheters, with their 
high risks of infection and stenosis, can proba-
bly be avoided, and patients willing to start peri-
toneal dialysis can avoid temporary hemodialysis.
In our view, the IDEAL trial supports the cur-
rently recommended practice, in which most ne-
phrologists start patients on renal-replacement 
therapy on the basis of clinical factors rather than 
numerical criteria such as the estimated GFR 
alone.10 Early referral to a nephrologist, a well-
organized patient-education program, and care-
ful planning before dialysis is initiated are the 
cornerstones of such a strategy.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
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Systemic Therapy for a Genetic Skin Disease
Leena Bruckner-Tuderman, M.D.
With an area of almost 2 m2, the human skin 
forms a large physical barrier between the organ-
ism and the environment. Diseases of the skin 
can have a severely negative effect on the quality 
and length of life of the persons affected.
Although effective treatments have been de-
vised for common skin diseases, curative therapies 
do not exist for genetic skin disorders, of which 
there are nearly 400. There are too few patients 
within each group to provide an incentive for the 
pharmaceutical industry to develop drugs. Scien-
tists, however, have recognized the value of mono-
genic diseases as models for the investigation of 
therapeutic approaches. Preclinical testing of 
therapies involving genes, small interfering RNA 
(siRNA), proteins, and cells,1 both in animal mod-
els2 and in pilot trials with individual patients,3-5 
has fueled enthusiasm for evidence-based treat-
ments of genetic skin diseases.
The systemic therapy for a genetic skin dis-
ease described by Wagner and colleagues in this 
issue of the Journal6 represents a leap forward. 
These investigators describe a phase 1–2 clinical 
trial of allogeneic bone marrow transplantation 
or umbilical-cord blood transplantation to treat 
epidermolysis bullosa.
Epidermolysis bullosa is a heterogeneous group 
of disorders characterized by chronic epithelial 
fragility7; the key symptom in all forms is trauma-
induced skin blistering. It is caused by the muta-
tion of 1 of at least 14 genes encoding proteins 
of the dermal–epidermal junction — a special-
ized basement-membrane zone that attaches the 
epidermis to the dermis.1,7 Patients have large, 
painful skin lesions, physical impairment, and a 
permanent need for assistance. For a patient with 
generalized epidermolysis bullosa, the estimated 
cost of symptomatic treatment of the skin alone 
exceeds $30,000 each year.
One of the most severe of the epidermolysis 
bullosa subtypes is generalized recessive dys-
trophic epidermolysis bullosa,8 which is caused 
by mutations in the gene encoding collagen VII 
(C7) and is characterized by a lack of this colla-
gen and its polymers — the anchoring fibrils — 
in the skin and mucosa. In recessive dystrophic 
epidermolysis bullosa, trauma-induced blistering 
and chronic, nonhealing wounds are associated 
with scarring. Joint contractures, mutilating de-
formities of the hands and feet, malnutrition, and 
growth retardation are secondary symptoms re-
quiring continuous multidisciplinary manage-
ment. A feared complication of this disorder is 
the development of squamous-cell carcinomas 
early in life. These cancers are aggressive, with 
a high propensity for metastasis.
Wagner and colleagues initiated their study af-
ter obtaining positive results on preclinical tests.9 
Seven children with recessive dystrophic epider-
molysis bullosa (between 15 months and 14.5 
years of age) were treated with immunomyeloab-
lative chemotherapy and subsequent bone marrow 
transplantation, umbilical-cord blood transplan-
tation, or both. Before treatment, all the children 
had extensive blistering, with varying degrees of 
involvement of other organs. Five of the seven 
graft recipients were alive between 130 and 799 
days after transplantation and had a substantial 
proportion of donor cells in the skin (median, 
20%). In five of the six children who could be 
evaluated, the authors observed an increase of C7 
at the dermal–epidermal junction. They did not, 
however, observe distinct anchoring fibrils. The 
children’s parents reported improved wound 
healing and less blistering within the first 100 
days. Presumably, the healthy hematopoietic do-
nor cells in the skin synthesized and secreted C7, 
which was then incorporated into the dermal–
epidermal junction.
These data are consistent with studies in mice 
indicating that 30 to 40% of physiologic C7 lev-
els is sufficient for clinically significant skin 
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